These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 4665234)

  • 21. Biochemical profile of idiopathic uric acid nephrolithiasis.
    Pak CY; Sakhaee K; Peterson RD; Poindexter JR; Frawley WH
    Kidney Int; 2001 Aug; 60(2):757-61. PubMed ID: 11473659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The importance of Magurlit in the prevention and dissolution of uric acid stones.
    Balogh F; Götz F; Köves S
    Ther Hung; 1980; 28(1):28-31. PubMed ID: 7281075
    [No Abstract]   [Full Text] [Related]  

  • 23. [The dissolution of uric acid calculi].
    Rometti A; Sanian H
    J Urol Nephrol (Paris); 1967 Dec; 73(12):924-6. PubMed ID: 5589224
    [No Abstract]   [Full Text] [Related]  

  • 24. Calcium restriction, thiazide, citrate, and allopurinol in calcium oxalate nephrolithiasis.
    Coe FL
    Acta Urol Belg; 1994 Jun; 62(2):25-9. PubMed ID: 8037000
    [No Abstract]   [Full Text] [Related]  

  • 25. Dissolution of uric acid calculi.
    Rodman JS; Williams JJ; Peterson CM
    J Urol; 1984 Jun; 131(6):1039-44. PubMed ID: 6726897
    [No Abstract]   [Full Text] [Related]  

  • 26. [On the oral litholysis of urate calculi].
    Eichler W
    Ther Ggw; 1969 Jan; 108(1):96-100. PubMed ID: 5763822
    [No Abstract]   [Full Text] [Related]  

  • 27. Uric acid calculi: results of conservative treatment.
    Petritsch PH
    Urology; 1977 Dec; 10(6):536-8. PubMed ID: 23599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The problem of idiopathic stone formers presenting with no metabolic disorders. Pathogenesis and management.
    Pak CY
    Contrib Nephrol; 1987; 58():164-71. PubMed ID: 3319402
    [No Abstract]   [Full Text] [Related]  

  • 29. [Treatment and prophylaxis of uric acid stones of the kidney by oral alkalinization].
    Kollwitz AA
    Dtsch Med Wochenschr; 1966 Jul; 91(28):1257-9. PubMed ID: 5942479
    [No Abstract]   [Full Text] [Related]  

  • 30. [The dissolution of uric acid calculi in kidney with ruberritrinic acid, aecina amorfa and citrates (uralyt-urato)].
    Picatoste-Patino J
    J Urol Nephrol (Paris); 1969 Dec; 75(12):Suppl 12:464+. PubMed ID: 5386920
    [No Abstract]   [Full Text] [Related]  

  • 31. [Treatment of uric lithiasis with citrates].
    Vargas F; Vargas R; Tallman B; Vivanco C; Neira N
    Rev Med Chil; 1970 Mar; 98(3):143-6. PubMed ID: 5471168
    [No Abstract]   [Full Text] [Related]  

  • 32. [Allopurinol induced electrolyte and metabolism changes in the urine of patients with kidney stones].
    Schwille PO; Jügelt U; Sigel A
    Urologe A; 1972 Jul; 11(4):185-9. PubMed ID: 5071601
    [No Abstract]   [Full Text] [Related]  

  • 33. [The kidney and hyperuricaemia (author's transl)].
    Tcherdakoff P
    Munch Med Wochenschr; 1973 Sep; 115(38):1607-11. PubMed ID: 4800872
    [No Abstract]   [Full Text] [Related]  

  • 34. [Oral dissolution and prevention of recurrences of uric-acid stones in the kidney by oral medication].
    Makrigiannis D; Gaca A
    Dtsch Med Wochenschr; 1970 Jun; 95(26):1383-7 passim. PubMed ID: 4393109
    [No Abstract]   [Full Text] [Related]  

  • 35. [On the management of urate calculi using the Uralyt-U preparation].
    Lange K
    Urologe; 1968; 7(4):194-200. PubMed ID: 5680488
    [No Abstract]   [Full Text] [Related]  

  • 36. [Dissolution and prevention of uric acid stones].
    Bukhman AA; Keiserman IuA
    Urol Nefrol (Mosk); 1973; 38(1):67-71. PubMed ID: 4571471
    [No Abstract]   [Full Text] [Related]  

  • 37. [Clinical evaluation of Uralyt-U Madaus preparation in the treatment of nephrolithiasis showing no shadows in radiograms].
    Wesolowski S; Cieślak A; Milewski J; Hartel-Ulkowska N
    Pol Tyg Lek; 1976 Nov; 31(45):1943-6. PubMed ID: 11452
    [No Abstract]   [Full Text] [Related]  

  • 38. [Dissolution of urate renal calculi by means of urine alkalinization. Presentation of 6 cases].
    Mantovani R; Sechi L; Della Corte C
    Minerva Urol; 1976; 28(3):142-5. PubMed ID: 1018709
    [No Abstract]   [Full Text] [Related]  

  • 39. In vivo 31P-MRS assessment of muscle-pH, cytolsolic-[Mg2+] and phosphorylation potential after supplementing hypokaliuric renal stone patients with potassium and magnesium salts.
    Mairiang E; Hanpanich P; Sriboonlue P
    Magn Reson Imaging; 2004 Jun; 22(5):715-9. PubMed ID: 15172066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduction of renal stone risk by potassium-magnesium citrate during 5 weeks of bed rest.
    Zerwekh JE; Odvina CV; Wuermser LA; Pak CY
    J Urol; 2007 Jun; 177(6):2179-84. PubMed ID: 17509313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.